A research team at the University of California, Riverside (UC Riverside) in the US has evaluated a new device manufactured by tissue sampling devices maker Histologics.

Designed to collect biopsy samples for cervical cancer testing, the new fabric-based endocervical curettage features a fabric hook for sample collection.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The existing metal scraping devices that are used to procure a small sample of cells from the cervix are considered to be painful, and do not deliver consistent and accurate results.

Intended to simultaneously biopsy, trap and store tissue for transport to the lab, the new fabric hook is intended to be less painful and reduce patient discomfort.

UC Riverside School of Medicine obstetrics/gynaecology assistant clinical professor Justin Diedrich said that the fabric-based endocervical curettage yielded significantly less inadequate specimens, eliminating the need for repeat biopsies of the patient.

"This could be the difference between intervening early before someone develops cancer and waiting until it has grown larger."

During the study, the researchers assessed samples from 81 physician and nurse colposcopists who switched from conventional metal devices to the fabric-based version.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The pathology lab results obtained from both before and after the switch of devices were analysed.

Diedrich said: “Minimally invasive office procedures for evaluating the outside of the cervix have been around for at least ten years, but this is the first product to evaluate the inside of the cervix with such ease.

“Because the biopsy gets more tissue, it is able to find more pre-cancerous cells. This could be the difference between intervening early before someone develops cancer and waiting until it has grown larger.”

Expected to provide better results with increased patient satisfaction, the device does not require a colposcopist clinician to handle the specimen or clean biopsy devices, decreasing the contamination risk.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact